Psychiatrist

Democratic Congressman Says Trump Admin Signals Revolutionary Shift on Drug Policy Reform

Democratic Congressman Lou Correa believes the Trump administration presents an unprecedented opportunity to transform American drug policy.

Read More

Ketamine Study Yields Surprising Findings That Could Change Depression Treatment

A new study from Stanford University has uncovered unexpected results about ketamine’s role in treating depression.

Read More

Positive Data Shows Promise of 5-MeO-DMT in Patients When Used With SSRIs

This trial marks a significant departure and may reshape how clinicians combine traditional antidepressants and psychedelic therapy.

Read More

Historic: Texas Invests $50 Million into Ibogaine Research

Texas has taken a bold step in mental health research by allocating $50 million to fund clinical trials of ibogaine.

Read More

2025 Ketamine Practitioner Intelligence Research Report

What are ketamine practitioner's biggest pain points? Our 2025 Ketamine Practitioner Intelligence Research Report breaks it down.

Read More

Colorado Governor Signs Bill Allowing Psychedelic Conviction Pardons

Colorado Governor Jared Polis has signed a new bill allowing people with past psychedelic drug convictions to apply for pardons.

Read More

Breakthrough Study Reveals Unexpected Allies in Eating Disorder Treatment

In a large study, cannabis and psychedelics emerged as the most highly rated treatments for treating eating disorders.

Read More

Johnson & Johnson’s Spravato Surges Toward Blockbuster Status

Johnson & Johnson's depression nasal spray Spravato continues its impressive growth trajectory, generating $414 million in Q2 2025 revenue.

Read More

7 Hidden Revenue Leaks Killing Your Ketamine Practice’s Profitability

These revenue leaks often remain invisible until they accumulate into thousands of lost income each month. Let's help you fix

Read More

Spravato Nasal Spray to Be Subsidized in Australia for Treatment Resistant Depression

The Australian government has announced that Spravato will be added to the Pharmaceutical Benefits Scheme starting July 1.

Read More

Explore Psychedelic Therapy Regions